Fluidigm Summer 2011 eNewsletter Focuses On Cancer Research

Fluidigm has announced its Summer 2011 eNewsletter - an informative publication dedicated to providing an insight into the latest innovations in integrated fluidic circuit (IFC) technology and topical applications development which will be of interest to researchers involved with gene expression, SNP genotyping and sample preparation for next generation sequencing.

In the Summer 2011 issue, researchers from the National Cancer Centre, Singapore, KK Women's & Children's Hospital, and the Singapore General Hospital report upon their evaluation of nanofluidics technology using DNA extracted from peripheral blood and buccal wash samples for high-throughput SNP Genotyping in a clinical setting.

Another independent paper presented in the newsletter discusses how single-cell gene expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene-based vaccines. The paper describes how researchers at the National Cancer Institute, Rockville, MD, USA gained an understanding of the mechanism of protective immunity mediated by CDS T cells, how the process is dependent upon the definition of heterogeneity, and also how immune responses are generated by different vaccines.

An abstract of a new poster from Fluidigm in conjunction with BD Biosciences describes a protocol where flow cytometry is paired with gene expression analysis to discriminate variation in phenotype and gene expression at the single-cell level and discusses how they may be pivotal in the differentiation of stem cells.

Complimenting the poster and independent customer research publications, the Summer 2011 newsletter also provides an introduction to Fluidigm's new assays for gene expression, genotyping and and target-specific primers for targeted resequencing as well as a new 192.24 Dynamic Array™ Integrated Fluidic Circuit (IFC) for high sample throughput SNP genotyping.

The Summer 2011 edition of the Fluidigm Corporation Community Newsletter is now available free to download from www.fluidigm.com/home/fluidigm/email/Q2_2011.html

Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm's proprietary microfluidic systems consist of instruments and consumables, including chips and reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets three microfluidic systems including eight different commercial chips to leading pharmaceutical and biotechnology companies, academic institutions and Ag-Bio companies.  For more information, please visit www.fluidigm.com.

* Fluidigm, the Fluidigm logo, BioMark and Dynamic Array NanoFlex are trademarks or registered trademarks of Fluidigm Corporation.
* Cautionary Note About Forward-Looking Statements:  This press release contains "forward-looking" statements within the meaning of federal securities laws. Forward-looking statements include, among others, statements concerning or implying the performance attributes of Fluidigm's products and their ability to contribute to the effectiveness or cost of research studies. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by these forward-looking statements. Fluidigm's business, revenues, and operating results are and will be subject to numerous risks and uncertainties, including (among others) risks relating to market acceptance of our products, the potential for quarterly variations in our operating results, our ability to successfully launch new products and applications, competition in our primary markets, variability in our sales cycle, our need to expand our sales, marketing, and distribution capabilities, costs associated with our planned sales and research and development activities, risks associated with international operations, and our ability to attract and retain technical support personnel. In addition to these risks and uncertainties, investors should review the risks and uncertainties contained in Fluidigm's filings with the United States Securities and Exchange Commission, including risks and uncertainties identified in our registration statement on Form S-1 as declared effective on February 9, 2011.

European Headquarters

 

Fluidigm SARL
15 Avenue de Norvege
91140 Villebon sur Yvette
France

Technical Contact: Leila Smith

Media Contact: Dr Bill Bradbury

tel. +33-160-924240 (Technical) / +44-208-546-0869 (Media)

email leila.smith@fluidigm.com / info@primetek-solutions.com

 

Worldwide Headquarters

Fluidigm Corporation

7000 Shoreline Court

Suite 100, South San Francisco

CA 94080
USA

www.fluidigm.com